RC010
/ Reju Therapeutics
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
April 15, 2026
A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of RC010 Inhalation Powder in Healthy Participants
(clinicaltrials.gov)
- P1 | N=42 | Not yet recruiting | Sponsor: Nanjing Reju Therapeutics Co., Ltd
First-in-human • New P1 trial • Idiopathic Pulmonary Fibrosis
1 to 1
Of
1
Go to page
1